AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01986998
Drug: Oral Methylprednisolone 625 mg/24h x3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
Trial: NCT01147146
Drug: propofol, fentanyl, atracurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: general anesthesia
Trial: NCT00915343
Drug: hydrocortisone (modified release), oral tablet 20 and 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
Trial: NCT00915343
Drug: Hydrocortisone, oral tablet, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
Trial: NCT03976700
Drug: Bufei Jianpi granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
Trial: NCT03976700
Drug: Placebo Bufei Jianpi granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
Trial: NCT00360607
Drug: Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00360607
Drug: Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited
RxNorm normalized name: Dr. Smith's Diaper Rash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00967057
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally
Trial: NCT00360607
Drug: Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00360607
Drug: Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00851370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-Weekly
Trial: NCT02938923
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical testosterone gel 1%
Trial: NCT02938923
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive skin gel
Trial: NCT03400800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Trial: NCT00454805
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02558374
Drug: AR-13324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop once daily (QD), PM, OU
Trial: NCT05206578
Drug: AGT2, AGZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, q.d.
Trial: NCT05206578
Drug: AGT4, AGZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, q.d.
Trial: NCT04664959
Drug: Prolia® (Denosumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
Trial: NCT03110874
Drug: one-way education
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
Trial: NCT03110874
Drug: two-way education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
Trial: NCT03589560
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
Trial: NCT00866385
Drug: AZD8566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 6 mg oral solution dose
Trial: NCT02644135
Drug: Halo Oral Spray
RxNorm normalized name: HYDROLYZED ORYZANOL 50 mg in 1 g / ALOE PERRYI LEAF 50 mg in 1 g / ARGININE 30 mg in 1 g TOPICAL CREAM [DRUGGIST HONEY HALO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sprays per use, total = 9 sprays per day
Trial: NCT02644135
Drug: Halo Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sprays per use, total = 9 sprays per day
Trial: NCT03964935
Drug: Minocycline HCl 1mg Oral Powder
RxNorm normalized name: minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
Trial: NCT03312478
Drug: Blood draw for insulin auto-anti body tests*
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: N/A~Route of administration: N/A
Trial: NCT00706277
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil 0,25mcg/kg/hour
Trial: NCT00706277
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 100mcg
Trial: NCT02318771
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03673215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
Trial: NCT03673215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Trial: NCT03673215
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Trial: NCT00418938
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m\^2 IV (in the vein)
Trial: NCT02784275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00679705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5%, IV
Trial: NCT01482845
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
Trial: NCT01482845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
Trial: NCT00105937
Drug: OraVescent fentanyl citrate
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04528108
Drug: Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
Trial: NCT00546052
Drug: losartan potassium (+) hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
Trial: NCT02305862
Drug: Rosuvastatin 5mg
RxNorm normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug intervention
Trial: NCT02305862
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug intervention
Trial: NCT01558271
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01558271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721655
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
Trial: NCT01721655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
Trial: NCT00178178
Drug: Bupivicaine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Bupivicaine 0.5 %
Trial: NCT00178178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo
Trial: NCT01493336
Drug: capecitabine RTD
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single oral dose
Trial: NCT01411748
Drug: mikostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50000 unit/3 times a day, both for orally and by orogastric route
Trial: NCT04609189
Drug: Calcium carbonate/vitamin D3
RxNorm normalized name: calcium carbonate/vitamin D3 180 mg-5,000 unit ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Calcium Carbonate/Vitamin D3
Trial: NCT01823679
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00465959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01526512
Drug: metroCX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
Trial: NCT01691209
Drug: 1% Hydrocortison cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Hydrocortison cream applied to the skin
Trial: NCT03536455
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT01531283
Drug: combined acyl and desacyl ghrelin
RxNorm normalized name: gellan gum (low acyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
Trial: NCT01175785
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02116010
Drug: E. coli Phages cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
Trial: NCT02116010
Drug: P. Aeruginosa, Phages cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
Trial: NCT00221403
Drug: Valproate Oral Solution
RxNorm normalized name: valproate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid, BID dosing.
Trial: NCT02600507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00967590
Drug: RO5036505
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380mg iv infusion once weekly for 8 weeks
Trial: NCT00967590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv infusion once weekly for 8 weeks
Trial: NCT00779285
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
Trial: NCT04026997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02389361
Drug: Zaldiar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
Trial: NCT03072147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
Trial: NCT00707330
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week
Trial: NCT01923909
Drug: Intra-articular corticosteroid injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
Trial: NCT04817722
Drug: Intravenous Solution
RxNorm normalized name: Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative hydration
Trial: NCT01916720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT00621504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Trial: NCT00621504
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Trial: NCT00002553
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01165450
Drug: Vehicle only
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Trial: NCT00849797
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg Tablet
Trial: NCT00849797
Drug: Trileptal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Tablet
Trial: NCT01262235
Drug: TKM-080301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose IV infusion.
Trial: NCT01748344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None active
Trial: NCT00918814
Drug: LIPO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT00918814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01730846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03809052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsules for oral use
Trial: NCT01950234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01872728
Drug: Bilateral facial block after general anesthesia before surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
Trial: NCT01018862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Trial: NCT00664248
Drug: IDP-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT00664248
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT00664248
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT02708251
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04372641
Drug: p97 Inhibitor CB-5339 Tosylate
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03622099
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
Trial: NCT01777152
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Trial: NCT01777152
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Trial: NCT00743093
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
Trial: NCT03164382
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
Trial: NCT00743093
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
Trial: NCT00820534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 2 hous during waking hours for 96 hours
Trial: NCT01096329
Drug: Intrinsa® Patch and Testosterone Spray 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days